BTG Plc develops, manufactures and supplies drugs used in the treatment of neurological disorders. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine and Licensing. The Specialty Pharmaceuticals segment offers three marketable products: CroFab, DigiFab and Voraxaze. The Interventional Medicine segment represents the portfolio of beads and brachytherapy products acquired with Biocompatibles. The Licensing segment includes revenues from its licensed portfolio of intellectual property as well as income from the acquired Biocompatibles business. BTG was founded in 1981 and is headquartered in London, the United Kingdom.